Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery
Primary Purpose
Coronary Disease, Coronary Artery Bypass Grafting
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Enoxaparin
Sponsored by

About this trial
This is an interventional treatment trial for Coronary Disease focused on measuring unfractionated heparin, enoxaparin, low molecular weight heparin, bypass surgery, bleeding
Eligibility Criteria
Inclusion Criteria:
- Patients aged 35-75 years with 3-vessel coronary artery disease (CAD)
- Candidates to elective CABG
Exclusion Criteria:
- Other additional (valve, carotid, etc.) simultaneous surgery required,
- Off-pump surgery,
- Any altered liver and kidney laboratory parameters,
- A history of any haemorrhagic disorders,
- Platelet count <100,000 and >450.000/μL,
- Treatment with ticlopidine or clopidogrel in the last month.
Sites / Locations
- Institute of Cardiology - S. Camillo Hospital
Outcomes
Primary Outcome Measures
Haemoglobin Concentration
Haematocrit
Platelet count
Transfusion Units
Secondary Outcome Measures
Full Information
NCT ID
NCT00420667
First Posted
January 8, 2007
Last Updated
November 7, 2022
Sponsor
G. d'Annunzio University
1. Study Identification
Unique Protocol Identification Number
NCT00420667
Brief Title
Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery
Official Title
Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
January 2007
Overall Recruitment Status
Completed
Study Start Date
November 2004 (Actual)
Primary Completion Date
March 2005 (Actual)
Study Completion Date
May 2005 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
G. d'Annunzio University
4. Oversight
5. Study Description
Brief Summary
Because the impairment of platelet function may cause excess peri-operative bleeding, pre-operative aspirin discontinuation and heparin bridging are common at cardiac surgery. We aimed to evaluate the impact of a low-molecular-weight-heparin (LMWH), enoxaparin, and unfractionated heparin (UFH) on coagulation parameters and peri-operative bleeding in patients undergoing elective coronary artery bypass grafting (CABG) surgery after aspirin discontinuation.
The specific hypothesis of this study was that a 12 h interval is sufficient not to cause excess peri-operative bleeding, and is therefore an optimal compromise between antithrombotic efficacy and haemorrhagic safety.
Detailed Description
Since LMWH provide many pharmacokinetic advantages compared with UFH, and since they are a valid substitution for UFH in a number of settings, such as non-ST elevation acute coronary syndromes and prevention of venous thromboembolism, LMWH may provide a useful bridge to revascularization after aspirin discontinuation in patients undergoing CABG surgery. Obstacles to the spreading of this practice are mainly the absence of solid evidence of equivalence (or superiority) as to efficacy in this setting, and the proof of equal safety, namely the absence of excess bleeding because some studies have suggested an increased number of haemorrhagic complications after LMWH, particularly with the use of higher doses. This might here be a problem, as patients are here generally at high risk of thrombotic events and for this reason need higher doses than for prevention of venous thromboembolism.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Disease, Coronary Artery Bypass Grafting
Keywords
unfractionated heparin, enoxaparin, low molecular weight heparin, bypass surgery, bleeding
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Enoxaparin
Primary Outcome Measure Information:
Title
Haemoglobin Concentration
Title
Haematocrit
Title
Platelet count
Title
Transfusion Units
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged 35-75 years with 3-vessel coronary artery disease (CAD)
Candidates to elective CABG
Exclusion Criteria:
Other additional (valve, carotid, etc.) simultaneous surgery required,
Off-pump surgery,
Any altered liver and kidney laboratory parameters,
A history of any haemorrhagic disorders,
Platelet count <100,000 and >450.000/μL,
Treatment with ticlopidine or clopidogrel in the last month.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raffaele De Caterina, MD, PhD
Organizational Affiliation
Institute of Cardiology - G. d'Annunzio University, Chieti
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute of Cardiology - S. Camillo Hospital
City
Chieti
State/Province
CH
ZIP/Postal Code
66100
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
15466654
Citation
Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA; American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004 Oct 5;110(14):e340-437. No abstract available. Erratum In: Circulation. 2005 Apr 19;111(15):2014.
Results Reference
background
PubMed Identifier
15582312
Citation
Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W; VA Cooperative Study Group #207/297/364. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol. 2004 Dec 7;44(11):2149-56. doi: 10.1016/j.jacc.2004.08.064.
Results Reference
background
PubMed Identifier
12397188
Citation
Mangano DT; Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002 Oct 24;347(17):1309-17. doi: 10.1056/NEJMoa020798.
Results Reference
background
PubMed Identifier
11156107
Citation
Dacey LJ, Munoz JJ, Johnson ER, Leavitt BJ, Maloney CT, Morton JR, Olmstead EM, Birkmeyer JD, O'Connor GT; Northern New England Cardiovascular Disease Study Group. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg. 2000 Dec;70(6):1986-90. doi: 10.1016/s0003-4975(00)02133-0.
Results Reference
background
PubMed Identifier
7695387
Citation
Ferraris VA, Ferraris SP. 1988: Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Updated in 1995. Ann Thorac Surg. 1995 Apr;59(4):1036-7. doi: 10.1016/0003-4975(95)00023-e. No abstract available.
Results Reference
background
PubMed Identifier
15276512
Citation
Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg. 2004 Aug;78(2):527-34; discussion 534. doi: 10.1016/j.athoracsur.2004.02.088.
Results Reference
background
PubMed Identifier
2404046
Citation
Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson WG. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol. 1990 Jan;15(1):15-20. doi: 10.1016/0735-1097(90)90168-o.
Results Reference
background
PubMed Identifier
16485701
Citation
Sirvinskas E, Veikutiene A, Grybauskas P, Cimbolaityte J, Mongirdiene A, Veikutis V, Raliene L. Influence of aspirin or heparin on platelet function and postoperative blood loss after coronary artery bypass surgery. Perfusion. 2006 Jan;21(1):61-6. doi: 10.1191/0267659106pf845oa.
Results Reference
background
PubMed Identifier
15383472
Citation
Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S. doi: 10.1378/chest.126.3_suppl.188S.
Results Reference
background
PubMed Identifier
15238596
Citation
Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 Jul 7;292(1):89-96. doi: 10.1001/jama.292.1.89.
Results Reference
background
PubMed Identifier
10750757
Citation
Clark SC, Vitale N, Zacharias J, Forty J. Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. Ann Thorac Surg. 2000 Mar;69(3):762-4; discussion 764-5. doi: 10.1016/s0003-4975(99)01366-1.
Results Reference
background
PubMed Identifier
11487039
Citation
Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost. 2001 Jul;86(1):488-98.
Results Reference
background
PubMed Identifier
11442521
Citation
Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001 Jul;88(7):913-30. doi: 10.1046/j.0007-1323.2001.01800.x.
Results Reference
background
PubMed Identifier
12354703
Citation
Jones HU, Muhlestein JB, Jones KW, Bair TL, Lavasani F, Sohrevardi M, Horne BD, Doty D, Lappe DL. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation. 2002 Sep 24;106(12 Suppl 1):I19-22.
Results Reference
background
PubMed Identifier
15836656
Citation
Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005 May;257(5):399-414. doi: 10.1111/j.1365-2796.2005.01477.x.
Results Reference
background
PubMed Identifier
16103244
Citation
Sun JC, Crowther MA, Warkentin TE, Lamy A, Teoh KH. Should aspirin be discontinued before coronary artery bypass surgery? Circulation. 2005 Aug 16;112(7):e85-90. doi: 10.1161/CIRCULATIONAHA.105.546697. No abstract available.
Results Reference
background
Learn more about this trial
Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery
We'll reach out to this number within 24 hrs